Results 201 to 210 of about 28,051 (225)

Refractory Chronic Cough: New Perspectives in Diagnosis and Treatment

Archivos de Bronconeumología (English Edition), 2013
In patients with chronic cough, nearly 40% of the population does not experience definitive improvement of their cough despite correctly applying the anatomic diagnosis. In many of these patients with refractory cough, laryngeal symptoms are frequent.
Adalberto, Pacheco, Ignacio, Cobeta, Carolin, Wagner   +2 more
openaire   +2 more sources

Cough Suppression Therapy in Patients With Chronic Refractory Cough and Oropharyngeal Dysphagia

American Journal of Speech-Language Pathology
Purpose: Chronic refractory cough (CRC), defined as cough lasting over 8 weeks despite medical intervention, is a prevalent condition with a number of associated comorbidities. Cough suppression therapy (CST) has been demonstrated to be a promising avenue for treating CRC by improving airway control and coordination.
ShengYing A. Chen, Jessica F. Kim, Priya Krishna, Ethan Simmons, Brianna K. Crawley, Thomas Murry   +5 more
openaire   +2 more sources

P5 Prevalence of refractory chronic cough in a tertiary cough clinic

It’s time to talk about cough and spit, 2018
Introduction and objectives In the past, some respiratory centres reported success rates of 98% when treating chronic cough based on identifying and treating underlying conditions such as asthma, nasal disease and gastro-oesophageal reflux. However, cases refractory to treatment of potential underlying causes are increasingly recognised, especially in
B Al-Sheklly, I Satia, H Badri, S Khalid, J Haines, AA Woodcock, JA Smith   +6 more
openaire   +1 more source

Current opinion in refractory and/or unexplained chronic cough

Current Opinion in Otolaryngology & Head & Neck Surgery
Purpose of review Otolaryngologists are vital to successfully managing chronic cough in adults. This review presents updates regarding rapidly evolving concepts in chronic cough. Recent findings Significant growth is occurring in chronic cough research, strengthening the evidence of
Stephanie, Misono, Carolyn K, Novaleski
openaire   +2 more sources

Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough

Drugs
Refractory chronic cough is a disabling disease with very limited therapeutic options. A better understanding of cough pathophysiology has led to the development of emerging drugs targeting cough receptors. Recent strides have illuminated novel therapeutic avenues, notably centred on modulating transient receptor potential (TRP) channels, purinergic ...
Laurent Guilleminault, Stanislas Grassin-Delyle, Stuart B. Mazzone   +2 more
openaire   +3 more sources

Gefapixant for Refractory or Unexplained Chronic Cough?

JAMA, 2023
Richard S, Irwin, J Mark, Madison
openaire   +2 more sources

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

Lancet, The, 2022
Lorcan McGarvey, Surinder S Birring, Peter V Dicpinigaitis   +2 more
exaly  

Cough hypersensitivity and chronic cough

Nature Reviews Disease Primers, 2022
Kian Fan Chung, Lorcan McGarvey, Woo-Jung Song   +2 more
exaly  

Is refractory chronic cough a genetic disease?

Epidemiology, 2023
Laurent Guilleminault, Pauline Chazelas, Boris Melloni, Corinne Magdelaine, Thomas Villeneuve, Danielle Brouquières, Anne-Sophie Lia, Laurent Magy   +7 more
openaire   +1 more source

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

Lancet Respiratory Medicine,the, 2020
Surinder S Birring, Lorcan McGarvey, Jaclyn A Smith   +2 more
exaly